CR20180388A - Formulaciones para el tratamiento del cáncer de vejiga - Google Patents
Formulaciones para el tratamiento del cáncer de vejigaInfo
- Publication number
- CR20180388A CR20180388A CR20180388A CR20180388A CR20180388A CR 20180388 A CR20180388 A CR 20180388A CR 20180388 A CR20180388 A CR 20180388A CR 20180388 A CR20180388 A CR 20180388A CR 20180388 A CR20180388 A CR 20180388A
- Authority
- CR
- Costa Rica
- Prior art keywords
- formulations
- proliposomal
- bladder cancer
- phospholipid
- dosage forms
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 8
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 title abstract 3
- 206010005003 Bladder cancer Diseases 0.000 title abstract 2
- 201000005112 urinary bladder cancer Diseases 0.000 title abstract 2
- 238000009472 formulation Methods 0.000 abstract 6
- 239000002552 dosage form Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000003904 phospholipids Chemical class 0.000 abstract 2
- GZDFHIJNHHMENY-UHFFFAOYSA-N Dimethyl dicarbonate Chemical compound COC(=O)OC(=O)OC GZDFHIJNHHMENY-UHFFFAOYSA-N 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 239000008135 aqueous vehicle Substances 0.000 abstract 1
- 206010005084 bladder transitional cell carcinoma Diseases 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000002483 medication Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- -1 phosphatidyl sodium glycerol Chemical compound 0.000 abstract 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 206010044412 transitional cell carcinoma Diseases 0.000 abstract 1
- 238000011269 treatment regimen Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen composiciones y métodos para la preparación y uso de formulaciones proliposomales y liposomales de agentes quimioterapéuticos. Las formulaciones proliposomales y liposomales de quimioterapéuticos, como así también los medicamentos y formas de dosificación que incluyen esas formulaciones se pueden utilizar con regímenes de tratamiento del cáncer de vejiga y el cáncer urotelial. Por ende, las formulaciones, medicamentos y formas de dosificación de la invención son adecuados para tratar los cánceres de vejiga mediante administración intravesical y para tratar los cánceres uroteliales. Las formulaciones de acuerdo con la invención incluyen (a) un taxano (por ej., paclitaxel, docetaxel) o cisplatino, (b) un primer fosfolípido, 1,2-dimiristoil¿sn¿glicero¿3¿fosfocolina (DMPC) y (c) un segundo fosfolípido, dimiristil fosfatidil glicerol sódico (DMPG). Las formulaciones proliposomales forman liposomas ante el contacto con un vehículo acuoso
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662275941P | 2016-01-07 | 2016-01-07 | |
| US201662275936P | 2016-01-07 | 2016-01-07 | |
| US201662421137P | 2016-11-11 | 2016-11-11 | |
| PCT/US2017/012720 WO2017120586A1 (en) | 2016-01-07 | 2017-01-09 | Formulations for treating bladder cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20180388A true CR20180388A (es) | 2018-09-11 |
Family
ID=59274569
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20180388A CR20180388A (es) | 2016-01-07 | 2017-01-09 | Formulaciones para el tratamiento del cáncer de vejiga |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11229602B2 (es) |
| EP (1) | EP3400072B1 (es) |
| JP (3) | JP6697541B2 (es) |
| KR (1) | KR20180103039A (es) |
| CN (2) | CN113181118A (es) |
| AU (1) | AU2017205337B2 (es) |
| BR (1) | BR112018013896A2 (es) |
| CA (1) | CA3009809A1 (es) |
| CL (1) | CL2018001838A1 (es) |
| CO (1) | CO2018007674A2 (es) |
| CR (1) | CR20180388A (es) |
| DK (1) | DK3400072T3 (es) |
| EA (1) | EA038653B1 (es) |
| ES (1) | ES2863659T3 (es) |
| HK (1) | HK1255212A1 (es) |
| IL (1) | IL260346B2 (es) |
| MX (2) | MX2018008267A (es) |
| MY (1) | MY198105A (es) |
| PE (1) | PE20181445A1 (es) |
| PH (1) | PH12018501451A1 (es) |
| SG (1) | SG11201805594PA (es) |
| WO (1) | WO2017120586A1 (es) |
| ZA (1) | ZA201804968B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018047074A1 (en) * | 2016-09-07 | 2018-03-15 | Cadila Healthcare Limited | Sterile injectable compositions comprising drug micelles |
| JP7096553B2 (ja) | 2016-11-11 | 2022-07-06 | ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ | 上部尿路上皮癌の治療方法 |
| WO2018169960A1 (en) * | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Nanoparticle formulations for enhanced drug delivery to the bladder |
| WO2019018619A1 (en) * | 2017-07-19 | 2019-01-24 | Tesorx Pharma, Llc | LIPOSOMAL FORMULATION OF PACLITAXEL FOR THE TREATMENT OF BLADDER CANCER |
| JP2021523808A (ja) * | 2018-05-04 | 2021-09-09 | ライパック オンコロジー エルエルシー | バルーンカテーテル |
| JP2022506612A (ja) * | 2018-11-02 | 2022-01-17 | テソリックス ファーマ， エルエルシー | リポソーム強化された腹腔内化学療法 |
| GB201900389D0 (en) | 2019-01-11 | 2019-02-27 | Queens Univ Of Belfast | Solvent and water-free lipid-based nanoparticles and their methods of manufacture |
| CN113189315B (zh) * | 2021-04-13 | 2024-01-23 | 山东省医疗器械产品质量检验中心 | 评价抗菌导尿管抗菌活性的体外动态模型及其使用方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1330938C (en) | 1985-10-18 | 1994-07-26 | Abdul R. Khokhar | Hydrophobic cis-platinum complexes efficiently incorporated into liposomes |
| US5415869A (en) * | 1993-11-12 | 1995-05-16 | The Research Foundation Of State University Of New York | Taxol formulation |
| US5902604A (en) | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| AU2869901A (en) * | 2000-02-04 | 2001-08-14 | Lipoxen Technologies Limited | Liposomes |
| US8658202B2 (en) * | 2001-04-25 | 2014-02-25 | Western University Of Health Sciences | Coated drug delivery formulations |
| EP1432403B1 (en) * | 2001-10-03 | 2010-07-28 | Celator Pharmaceuticals, Inc. | Liposome loading with metal ions |
| KR20050105451A (ko) | 2003-02-03 | 2005-11-04 | 네오팜 인코포레이티드 | 안정한 멸균 여과가능한 리포좀 캡슐화 탁산 및 다른항종양제 |
| CA2541117A1 (en) * | 2003-10-01 | 2005-05-06 | Children's Hospital & Research Center At Oakland | Lipophilic drug delivery vehicle and methods of use thereof |
| WO2005072776A2 (en) * | 2004-01-30 | 2005-08-11 | Instytut Farmaceutyczny | Liposomal formulations of the antineoplastic agents |
| WO2006015120A2 (en) * | 2004-07-28 | 2006-02-09 | Sd Pharmaceuticals, Inc. | Stable injectable composition of alpha tocopheryl succinate, analogues and salts thereof |
| EP2013016B8 (en) * | 2006-03-29 | 2014-10-08 | Wayne State University | Liposomal nanoparticles and other formulations of fenretinide for use in therapy and drug delivery |
| PL2076244T3 (pl) * | 2006-10-10 | 2017-05-31 | Jina Pharmaceuticals Inc. | Układy wodne do wytwarzania związków farmaceutycznych na bazie lipidów; kompozycje, sposoby, oraz ich zastosowanie |
| CN101322689B (zh) | 2007-06-11 | 2012-10-24 | 江苏先声药物研究有限公司 | 一种多西他赛长循环脂质体及其冻干粉针的制备方法 |
| WO2010009186A1 (en) | 2008-07-15 | 2010-01-21 | The Board Of Trustees Of The University Of Illinois | Liposome formulation having hydrophilic and hydrophobic pharmaceutical compounds co-encapsulated therein |
| US8956600B2 (en) * | 2009-08-10 | 2015-02-17 | Taiwan Liposome Co. Ltd. | Ophthalmic drug delivery system containing phospholipid and cholesterol |
| US20110166214A1 (en) | 2010-01-07 | 2011-07-07 | Innopharma, Llc | Methods and compositions for delivery of taxanes in stable oil-in-water emulsions |
| KR20150032939A (ko) * | 2012-05-09 | 2015-03-31 | 웨스턴 유니버시티 오브 헬스 사이언시스 | 프로리포좀 테스토스테론 제제 |
| CN103570766B (zh) * | 2012-08-09 | 2016-04-13 | 浙江海昶生物医药技术有限公司 | 一种新型铂类脂质体制剂及其制备方法 |
| CN103768018A (zh) * | 2012-10-17 | 2014-05-07 | 南京绿叶思科药业有限公司 | 一种卡巴他赛脂质体注射剂及其制备方法 |
| EP2968142A1 (en) | 2013-03-13 | 2016-01-20 | Mallinckrodt LLC | Liposomal cisplatin compositions for cancer therapy |
| BR112015022819A8 (pt) * | 2013-03-13 | 2019-11-26 | Mallinckrodt Llc | método para a preparação de um taxano lipossomal, composição compreendendo um lipossoma e taxano lipossomal |
| JP7096553B2 (ja) * | 2016-11-11 | 2022-07-06 | ウエスタン ユニバーシティ オブ ヘルス サイエンシーズ | 上部尿路上皮癌の治療方法 |
-
2017
- 2017-01-09 CR CR20180388A patent/CR20180388A/es unknown
- 2017-01-09 MY MYPI2018001179A patent/MY198105A/en unknown
- 2017-01-09 DK DK17736515.2T patent/DK3400072T3/da active
- 2017-01-09 JP JP2018500936A patent/JP6697541B2/ja not_active Expired - Fee Related
- 2017-01-09 ES ES17736515T patent/ES2863659T3/es active Active
- 2017-01-09 EA EA201891575A patent/EA038653B1/ru unknown
- 2017-01-09 CN CN202110437727.6A patent/CN113181118A/zh active Pending
- 2017-01-09 MX MX2018008267A patent/MX2018008267A/es unknown
- 2017-01-09 AU AU2017205337A patent/AU2017205337B2/en not_active Ceased
- 2017-01-09 BR BR112018013896A patent/BR112018013896A2/pt not_active IP Right Cessation
- 2017-01-09 US US16/066,836 patent/US11229602B2/en active Active
- 2017-01-09 CA CA3009809A patent/CA3009809A1/en active Pending
- 2017-01-09 CN CN201780002340.XA patent/CN108136217B/zh active Active
- 2017-01-09 WO PCT/US2017/012720 patent/WO2017120586A1/en active Application Filing
- 2017-01-09 SG SG11201805594PA patent/SG11201805594PA/en unknown
- 2017-01-09 KR KR1020187000357A patent/KR20180103039A/ko not_active Application Discontinuation
- 2017-01-09 PE PE2018001211A patent/PE20181445A1/es unknown
- 2017-01-09 EP EP17736515.2A patent/EP3400072B1/en active Active
-
2018
- 2018-06-28 IL IL260346A patent/IL260346B2/en unknown
- 2018-07-03 MX MX2020013858A patent/MX2020013858A/es unknown
- 2018-07-04 CL CL2018001838A patent/CL2018001838A1/es unknown
- 2018-07-06 PH PH12018501451A patent/PH12018501451A1/en unknown
- 2018-07-24 ZA ZA2018/04968A patent/ZA201804968B/en unknown
- 2018-07-25 CO CONC2018/0007674A patent/CO2018007674A2/es unknown
- 2018-11-09 HK HK18114340.8A patent/HK1255212A1/zh unknown
-
2019
- 2019-10-15 JP JP2019188572A patent/JP2020002181A/ja not_active Withdrawn
-
2021
- 2021-05-19 US US17/324,584 patent/US20210267896A1/en not_active Abandoned
-
2022
- 2022-09-12 JP JP2022144431A patent/JP2022168210A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018007674A2 (es) | Formulaciones para el tratamiento del cáncer de vejiga | |
| CO2022002685A2 (es) | Nanopartículas lipídicas mejoradas para el suministro de ácidos nucleicos | |
| UY37168A (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
| UY37435A (es) | Pirrolidinas sustituidas y métodos para usarlas | |
| BR112018010418A8 (pt) | complexo de agente quimioterápico em microbolhas para terapia sonodinâmica | |
| BR112018003985A2 (pt) | macrociclos peptidomiméticos e usos dos mesmos | |
| AR110419A1 (es) | Profármacos de principios activos citotóxicos con grupos enzimáticamente escindibles | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| UY37832A (es) | Dihidrooxadiazinonas | |
| DOP2016000118A (es) | Tienopirimidinas como inhibidores mknk1 y mknk2 | |
| CO2017005968A2 (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
| DOP2016000007A (es) | Pirazolpiridinas sustituidas | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| ECSP18060820A (es) | Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano | |
| CO2022008817A2 (es) | Macrociclos para uso en el tratamiento de enfermedades | |
| AR102778A1 (es) | Composición farmacéutica, su preparación y sus usos | |
| BR112019004906A2 (pt) | combinação incluindo abx196 para o tratamento de câncer | |
| BR112018068000A2 (pt) | composições de nanolipossomas de geração de docetaxel direcionados ao receptor a2 de efrina (epha2) | |
| MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
| CL2019003288A1 (es) | Una combinación farmacéutica para el tratamiento de un cáncer. | |
| DOP2017000069A (es) | Veliparib en combinación con carboplatino y paclitaxel para el tratamiento del cáncer pulmonar no microcítico en fumadores | |
| UY38319A (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción |